Vivimed Labs Limited
Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.
What Vivimed files
- Others28
- Important21
- Updates11
- Board Meeting6
- Results3
Vivimed Labs' board approved consolidated Q3 FY26 results: Revenue ₹159.89 Cr, Loss ₹16.55 Cr. Auditors issued a qualified report, flagging unprovided loan interest, pending forensic audit impact, and unsupported commission provisions, significantly impacting reported figures. #VIVIMEDLAB
Vivimed Labs' board approved Q2/H1 consolidated results with a reported loss. Auditors issued a qualified opinion due to unrecorded interest of ₹30.71 Cr for H1, pushing the total loss to ₹43.51 Cr. Board also approved a pre-packaged insolvency process (shareholder approval pending) and expects trading suspension revocation.
Vivimed Labs' recent board meeting saw key decisions. The consolidated financial results for the quarter ended June 30, 2025, were approved. While reporting a ₹5.49 Cr net loss, auditors highlighted a major concern: ₹14.98 Cr in unrecorded interest expenses could push the consolidated loss to ₹20.48 Cr. The company also...
Vivimed Labs' board has approved financial results for the quarter ended June 30, 2025. Consolidated revenue was Rs 21.77 crore. Auditors qualified results due to Rs 14.98 crore in unrecorded interest expenses, resulting in an adjusted consolidated loss of Rs 20.48 crore (EPS: -Rs 2.47). The company faces Rs 374.82...
Vivimed Labs has announced a board meeting approving the audited financial results for the year ended March 31, 2025. Consolidated revenue was Rs 120.67 Cr, down from Rs 149.07 Cr last year. The company narrowed its consolidated net loss to Rs 31.96 Cr from Rs 45.45 Cr previously. Operating costs...